Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 16/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 16/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 16/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 15/20 | 0.70 |
| ▸ | TSHR | P16473 | 12/20 | 0.70 |
| ▸ | USP2 | O75604 | 10/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34462816 | 0.86 | CYP1A2 (0.71) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL34462921 | 0.84 | CYP1A2 (0.71) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL5752435 | 0.83 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL4861102 | 0.83 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL3452299 | 0.83 | CYP1A2 (0.69) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL34462910 | 0.82 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL34462729 | 0.81 | MAP4K4 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL14486766 | 0.80 | CYP3A4 (0.51) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL34462796 | 0.79 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL2042230 | 0.78 | ALDH1A1 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725942-A1 | COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE | Sibylla Biotech S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1654238-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005009978-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | CYP1A2 1697/4885CYP3A4 1381/4885CYP2D6 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.